SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients
- 239 Downloads
There is a large inter-individual variation in the efficacy of valproic acid (VPA) against epilepsy. The genetic polymorphism influence of sodium channels on VPA response remains a matter of debate. The aim of the study was to explore the effect of SCN1A and SCN2A gene polymorphisms on VPA response in the treatment of epilepsy among Chinese patients.
A total of 354 epileptic patients with VPA treatment were genotyped for five single nucleotide polymorphisms (SNP), including SCN1A rs10188577 T>C, rs2298771 T>C, rs3812718 G>A, and SCN2A rs2304016 A>G, rs17183814 G>A. A binary logistic regression analysis was performed to evaluate the association of genotype with VPA antiepileptic effects, adjusting the influence of confounding factors.
Genotype distributions of all selected SNPs were consistent with the Hardy–Weinberg equilibrium in epilepsy patients. SCN1A rs3812718 and SCN2A rs2304016 were found to be significantly associated with VPA response, both in monotherapy and in VPA-based polytherapy. Patients with the rs3812718 A allele were more frequently seen in the VPA-responsive group (P < 0.05), and the rs2304016 G allele was related to an increased risk of resistance to VPA therapy (P < 0.05).
Our study revealed that SCN1A rs3812718 and SCN2A rs2304016 polymorphisms might be markers of VPA response in Chinese epilepsy patients.
KeywordsEpilepsy Valproic acid SCN1A SCN2A Antiepileptic efficacy
We thank all patients and their family members who contributed to this work. We thank Professor Shusen Sun from College of Pharmacy and Health Sciences at Western New England University, USA, for his valuable advice.
Contributions of authors
Zanling Zhang designed the study. Lihong Shi performed the data analysis and wrote the manuscript. Miaomiao Zhu, Huilan Li, and Zhipeng Wen recruited patients and conducted patients’ follow-up. Jia Luo and Cong Lin extracted the DNA. Xiaoping Chen reviewed the manuscript and critically revised the intellectual content of the manuscript.
This work was supported by a grant from the Natural Science Foundation of Hunan Province (no. 2017JJ2398).
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of Xiangya Hospital Central South University Medical Ethics Committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077CrossRefPubMedGoogle Scholar
- 6.Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010Google Scholar
- 21.Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, Liu D, Zhou HH, Liu ZQ (2012) Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 18:566–572CrossRefPubMedGoogle Scholar
- 22.Zhou BT, Zhou QH, Yin JY, Li GL, Xu XJ, Qu J, Liu D, Zhou HH, Liu ZQ (2012) Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 39:379–384CrossRefPubMedGoogle Scholar
- 23.Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP, Condino F, Durisotti C, Elia M, Giallonardo AT, Iudice A, Labate A, la Neve A, Michelucci R, Muscas GC, Paravidino R, Zaccara G, Zucca C, Zara F, Perucca E (2011) A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52:e40–e44CrossRefPubMedGoogle Scholar
- 29.Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A 102:5507–5512CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW, Lui CH, Sin NC, Wong KS, Baum L (2008) Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18:989–998CrossRefPubMedGoogle Scholar